ª`·N¤O¯Ê³´¹L°Ê¯g
Attention Deficit Hyperactivity Disorder, ADHD

¸ê®Æ¨Ó·½¡G¬ü°ê°ê®aºë¯«½Ã¥Í¬ã¨s°|
¡]National Institute of Mental Health¡^
½Ķ¡G¤¤¤sÂå¾Ç¤j¾Çªþ³]Âå°|ºë¯«¬ì
¨àµ£«C¤Ö¦~¹Î¶¤

  °Ý¡G¤°»ò¬Oª`·N¤O¯Ê³´¹L°Ê¯g¡]Attention Deficit Hyperactivity Disorder, ADHD¡^¡H

 
µª¡G ADHD«üªº¬O¤@¸s¤¬¬Û¦³ÃöÁpªººC©Ê¯«¸g¥Í²z¯e¯f¡A³o¨Ç¯e¯f·|§«Ãª­Ó¤Hªº¯à¤O¡A¥H­PµLªk¥H¨äµo®i¶¥¬q¾A¦Xªº¤è¦¡¨Ó½Õ¸`¬¡°Ê¶q¡]¹L°Ê¡^¡B§í¨î¦æ¬°¡]½Ä°Ê¡^©M±Mª`¦b¸Ó°µªº¨Æ±¡¤W¡]¤£±M¤ß¡^¡CADHDªº®Ö¤ß¯gª¬¥]¬AµLªk«ùÄòª`·N¤O©M±M¤ß¡B¤£¦X¨äµo®i¶¥¬qªº¬¡°Ê¶q¡B¤À¤ß©M½Ä°Ê¡C±w¦³ADHDªº«Ä¤l¦b¦h­Ó³õ¦X¡A¥]¬A®aùØ¡B¾Ç®Õ©M¦P¾«Ãö«Y¡A¥\¯à³£¦³¨ü·l¡CADHD¤]³QÅã¥Ü¥X¹ï¾Ç·~ªí²{¡B¾·~¦¨´N©MªÀ¥æ±¡ºüµo®i¤W¦³ªø´Áªº¤£¨}¼vÅT¡C¦³ADHDªº¤p«Ä·|¸gÅç¨ì¦b½Ò°ó¤WµLªkÀR§¤©M±M¤ß¡A¥H¤Î¦]³o¨Ç¦æ¬°²£¥Íªº­t­±µ²ªG¡F¥L­Ì³Q¦P¾«©Úµ´¡A¦Ó¥B¥i¯à¥X²{¦hºØ¤zÂZ¦æ¬°¡A¥L­Ìªº¾Ç·~©MªÀ¥æ§xÃø¦³²`»·¥Bªø´Áªº«áªG¡C³o¨Ç«Ä¤l¦³¸û°ªªº¨ü¶Ë¤ñ¨Ò¡C·í¥L­Ìªø¤j¤@ÂI¡A¥¼¸gªvÀøªºADHD±wµ£¡A¦pªG¦X¨Ö¦æ¬°³W½d»Ùê¡]conduct disorder¡^¡A¥i¯à¥X²{ÃĪ«ÀݥΡB¤ÏªÀ·|¦æ¬°¡A¥H¤Î¦U¦¡¦U¼Ëªº¶Ë®`¡C¹ï«Ü¦h¤H¨Ó»¡¡AADHDªº½ÄÀ»«ùÄò¨ì¦¨¤H´Á¡C

 
  °Ý¡GADHDªº¯gª¬¦³­þ¨Ç¡H
 
榭G
  1. ¤£±M¤ß¡X¤£±M¤ßªº¤H«ÜÃøºû«ù¥L­Ìªº¤ß«ä¦b¤@¥ó¨Æ±¡¤W¡A¦Ó¥B«Ü¥i¯à¦b¶È¶È´X¤ÀÄÁ«á´N¹ï¤@¥ó¨Æ·P¨ìµL²á¡C¦³·NÃÑ¥B¬G·N¦a¶°¤¤ª`·N¤O¨Ó²Õ´©M§¹¦¨¨Ò¦æ©Êªº¤u§@¥i¯à¦³§xÃø¡C

  2. ¹L°Ê¡X¹L°Êªº¤H¬Ý°_¨ÓÁ`¬O°Ê­Ó¤£°±¡A¥L­Ì¤£¯àÀRÀR§¤µÛ¡F¥L­Ì½Ä¨Ó½Ä¥h©Î¤£°±¦aÁ¿¸Ü¡A¾ã¸`½Ò¤@ª½¦wÀR§¤µÛ·|¬O¤£¥i¯àªº¥ô°È¡C¥L­Ì¥i¯à¦b©Ð¶¡¤º¥|³Bº©¹C¡B¦b®y¦ì¤Wį°Ê¡B·n°Ê¥L­Ìªº¸}¡B¸IIJ¨C¤@¼ËªF¦è¡A©Î¬OºV¹]µ§µo¥X¾¸­µ¡C¥L­Ì¤]¥i¯à¦³«Ü±j¯Pªº§¤¥ß¤£¦wªº·Pı¡C

  3. ½Ä°Ê¡X¹L¤À½Ä°Êªº¤H¬Ý°_¨ÓµLªk§í¨î¥L­Ìªº¥ß§Y¤ÏÀ³©Î¦b¦æ°Ê¤§«e¥ý«ä¦Ò¡A¦]¦¹¡A¥L­Ì¥i¯à°n¥X°ÝÃDªºµª®×©Î¤£«ê·íªº§åµû¡A©Î¬O¨S¦³¬Ý´N½Ä¨ì¸ô¤W¡C¥L­Ìªº½Ä°Ê©Ê¥i¯àÅý¥L­Ì«ÜÃø¥hµ¥«Ý¥L­Ì·Q­nªºªF¦è©Î¬O¦b¹CÀ¸®Éµ¥¨ì½ü¥Lªº®É­Ô¡C¥L­Ì¥i¯à±q§Oªº¤p«Ä¤â¤¤·m¹Lª±¨ã¡A©Î¬O¦b¥L­ÌÃø¹L®É¥´¤H¡C
  °Ý¡GADHD¦p¦ó¶EÂ_¡H
 
µª¡G µª¡GADHD¥i¥H³z¹L¸g¹L¨}¦n´ú¸Õªº¶EÂ_·|½Í¤èªk³Q¥i¾a¦a¶EÂ_¡A¶EÂ_¬O°ò©ó«Ä¤l¹L¥hªº±¡ªp¡]history¡^©M¦b«Ä¤l¤é±`ªºÀô¹Ò¤¤¥iÆ[¹î¨ìªº¦æ¬°¡C²z·Q±¡ªp¤U¡A½Ã¥Í·ÓÅ@ÂåÀø¤H­û­n¤U¤@­Ó¶EÂ_¥²»Ý¥]¬A¨Ó¦Û®aªø©M¦Ñ®vªº¸ê®Æ¡AÃöÁ䪺­n¯À¥]¬A²[»\©Ò§e²{¥X¯gª¬ªº§¹¾ã¥v¡BŲ§O¶EÂ_¡B¥i¯àªº¦@¯f±¡ªp¡A¥H¤ÎÂåÀø¡Bµo®i¡B¾Ç®Õ¡B¤ß²zªÀ·|©M®a±Ú¥v¡C½T©w¤°»ò­ì¦]«P¨Ï­n¨Dµû¦ô¥H¤Î¹L¥h´¿¥Î¹L¦óºØ¤è¦¡³B²z¬O«Ü¦³¥Îªº¡CµM¦Ó¡A¥Ø«e¨S¦³¿W¥ßªºADHDÀË´ú¤u¨ã¡C¤£¥u¬OADHD¡A¤j³¡¤Àªººë¯«¯e¯f¡A¥]¬A¨ä¥L¦pºë¯«¤Àµõ¯g©M¦Û³¬¯gµ¥·|³y¦¨´Ý»Ùªº¯e¯f¡A¤]¬O¦p¦¹¡C
  °Ý¡G¦h¤Ö¨àµ£³Q¶EÂ_¦³ADHD¡H
 
µª¡G ADHD¥i¥H³z¹L¸g¹L¨}¦n´ú¸Õªº¶EÂ_·|½Í¤èªk³Q¥i¾a¦a¶EÂ_¡A¶EÂ_¬O°ò©ó«Ä¤l¹L¥hªº±¡ªp¡]history¡^©M¦b«Ä¤l¤é±`ªºÀô¹Ò¤¤¥iÆ[¹î¨ìªº¦æ¬°¡C²z·Q±¡ªp¤U¡A½Ã¥Í·ÓÅ@ÂåÀø¤H­û­n¤U¤@­Ó¶EÂ_¥²»Ý¥]¬A¨Ó¦Û®aªø©M¦Ñ®vªº¸ê®Æ¡AÃöÁ䪺­n¯À¥]¬A²[»\©Ò§e²{¥X¯gª¬ªº§¹¾ã¥v¡BŲ§O¶EÂ_¡B¥i¯àªº¦@¯f±¡ªp¡A¥H¤ÎÂåÀø¡Bµo®i¡B¾Ç®Õ¡B¤ß²zªÀ·|©M®a±Ú¥v¡C½T©w¤°»ò­ì¦]«P¨Ï­n¨Dµû¦ô¥H¤Î¹L¥h´¿¥Î¹L¦óºØ¤è¦¡³B²z¬O«Ü¦³¥Îªº¡CµM¦Ó¡A¥Ø«e¨S¦³¿W¥ßªºADHDÀË´ú¤u¨ã¡C¤£¥u¬OADHD¡A¤j³¡¤Àªººë¯«¯e¯f¡A¥]¬A¨ä¥L¦pºë¯«¤Àµõ¯g©M¦Û³¬¯gµ¥·|³y¦¨´Ý»Ùªº¯e¯f¡A¤]¬O¦p¦¹¡C

  °Ý¡GADHD¤£¬O¦³¤£¦PªºÃþ«¬¶Ü¡H
 
µª¡G ®Ú¾ÚDSM-IV¡ADSM¡]ºë¯«¯e¯f¶EÂ_¤Î²Î­p¤â¥U¡^ªº²Ä¥|¥B³Ì·sªºª©¥»¡AÁöµM¤j³¡¤Àªº¤H³£¦³¤£±M¤ß©M¹L°Ê¡X½Ä°Êªº¯gª¬¡A¦³¤@¨Ç¤H¥u¦³¨ä¤¤¤@ºØ«¬ºA¸û¬°¥D­n¡]¦Ü¤Ö¦b¹L¥hªº¤»­Ó¤ë¤¤¡^¡C

  °Ý¡G¾Ç®Õ¦p¦ó²o¯A¨ì¶EÂ_¡Bµû¦ô©MªvÀøADHD¡H
 
µª¡G Âå®v©M®aªø¥²»Ý¤F¸Ñ¦bÁp¨¹ªk¥O¤U¡A¦pªGÃhºÃ«Ä¤l¥i¯à¦³·|¼vÅT¾Ç·~¥\¯àªº»Ùê¡A¾Ç®Õ¥i¥H¶i¦æ¾A·íªºµû¦ô¡C³o­Ó¬Fµ¦³Ìªñ³Q´Ý»Ù±Ð¨|ªk¡]IDEA¡^ªº1997¦A±ÂÅv¡]the 1997 reauthorization of the Individuals with Disabilities Act¡^ªº¬I¦æ±ø¨Ò©Ò±j¤Æ¡A¦¹ªk«OÃÒ¤T¨ì¤G¤Q¤@·³ªº´Ý»Ù«Äµ£¦³¾A·íªºÀ°§U©M¤½¥ß±Ð¨|ªºÅv§Q¡C²Ä¤@¦¸¡A´Ý»Ù±Ð¨|ªk¯S§O¦C¥XADHD¬°¦X¥G¯S®í±Ð¨|ªº±¡ªp¡C¦pªG¾Ç®Õ©Ò°µªºµû¦ô¤£¨¬©Î¤£¾A·í¡A®aªø¥i¥H­n¨D¥Î¾Ç®Õªº¸g¶O¦A°µ¤@¦¸¿W¥ßªºµû¦ô¡C¦AªÌ¡A¤@¨Ç±w¦³ADHDªº«Ä¤l²Å¦X¥H¡u¨ä¥L°·±d¨ü·l¡vªºÃþ§O¦b¤½¥ß¾Ç®Õ±µ¨ü¯S®í±Ð¨|¡C¹ï³o¨Ç­Ó®×¡A¯S±Ð¦Ñ®v¡B¾Ç®Õ¤ß²z®v¡B¾Ç®Õ¥DºÞ¡B¯Z¯Å¾É®v©M®aªø¡A¥²»Ýµû¦ô«Ä¤lªºªø³B©Mµu³B¡A¨Ã³]­p­Ó§O±Ð¨|­p¹º¡]Individualized Education Program¡^¡Cµ¹ADHD±wµ£ªº³o¨Ç¯S®í±Ð¨|ªº¨ó§U¥i¥H³z¹L´Ý»Ù±Ð¨|ªk¡]IDEA¡^Àò±o¡C

  °Ý¡GADHD¬O¿ò¶Ç¨Óªº¶Ü¡H
 
µª¡G ¬ã¨sÅã¥ÜADHD¦³®a±Ú¶É¦V¡A©Ò¥H¥i¯à¦³¿ò¶Çªº¦]¯À¡CADHDªº±wµ£³q±`¦Ü¤Ö¦³¤@­Óªñ¿Ë¤]¦³ADHD¡A¦Ó¥B¦Ü¤Ö¤T¤À¤§¤@¤p®É­Ô¦³ADHDªº¤÷¿Ë¡A¥L­Ìªº¤p«Ä¤]¦³ADHD¡C¹ï¥i¯à¦³¿ò¶Ç¬ÛÃö§ó¨ã»¡ªA¤Oªº¬O¡A·í¦P§ZÂù­M­L¨ä¤¤¤§¤@¦³¦¹¯e±w®É¡A¥t¤@­Ó«Ü¥i¯à¤]¦³¡C
  °Ý¡GADHD¦³¼W¥[¶Ü¡H¦pªG¦³¡A¬°¤°»ò¡H
 
µª¡G ¨S¦³¤H¯u¥¿ª¾¹DADHD¥»¨­ªº²±¦æ²v¬O§_¦³¼W¥[¡A¦ý¬O«Ü²M·¡ªº¬O¡A³Q¿ë»{¥X¨Ó±w¦³¦¹¯e¯f¦Ó±µ¨üªvÀøªº«Äµ£¼Æ¥Ø¦b¹L¥h¤Q¦~¦³´£°ª¡C¿ë»{©M´M¨DªvÀøªº¼W¥[¤@³¡¥÷¬O¦]¬°¤j²³¶Ç¼½´CÅ骺¿³½ì¡B®ø¶OªÌªº¤F¸Ñ¼W¥[¡A¥H¤Î¦³¦³®ÄªºªvÀø¤èªk¡CÃþ¦üªº±¡§Î²{¦b¤]¥i¨£©ó¨ä¥L°ê®a¡C³o­Ó¯e¯f¥»¨­ªºµo¥ÍÀW²v¬O§_¦³¼W¥[¤´µM¥¼ª¾¡A¦Ó¥B»Ý­n¬ã¨s¡C
  °Ý¡GADHD¥i¥H¦b±wµ£ªº¸£³¡±½´y¬Ý¥X¨Ó¶Ü¡H
 
µª¡G ¯«¸g¼v¹³ªº¬ã¨s¤w¸gÅã¥Ü¥XADHD±wµ£ªº¤j¸£©M«D±wµ£ªº¤j¸£¦³«Ü¤@­Pªº¤£¦P¡A±wµ£ªº¼Æ­Ó¤j¸£³¡¦ì©Mµ²ºc¡]«eÃB¸­¥Ö½è¡B¯¾ª¬Åé¡B°ò©³®Ö©M¤p¸£¡^¸û¤p¡A±wµ£ªº¾ã­Ó¤j¸£¤@¯ë¨Ó»¡¤ñ«D±wµ£¤p5¢M¡CÁöµM³o­Ó¥­§¡ªº®t²§«Ü¤@­P¡A¦ý¬O¦]¬°®t²§¤Ó¤p¦ÓµLªk¥Î¨Ó¶EÂ_¤@­Ó¤H¬O§_¦³ADHD¡C¦¹¥~¡A­Ó¤H¯à°÷«ùÄò±M¤ßªº¯à¤O©M¤ÏÀ³¤j¸£¬¡°Ê¤Oªº­p¶q¦³Ãö¡A¦bADHDªº±wªÌ¨­¤W¡A±±¨îª`·N¤Oªº¤j¸£°Ï°ì¬Ý°_¨Ó¸û¤£¬¡ÅD¡Aªí¥Ü¤j¸£¤¤¬Y¨Ç³¡¤À¸û§Cªº¬¡°Ê¤O©MµLªkºû«ù±Mª`¦³Ãö¡C

  °Ý¡G¾ÇÄÖ«eªº«Äµ£¥i¥H³Q¶EÂ_ADHD¶Ü¡H
 
榭G

¹ï¾ÇÄÖ«eªº«Äµ£¶EÂ_ADHD¬O¥i¯àªº¡A¦ý¬O¥i¯à¸û§xÃø¡A¦Ó¥BÀ³¸Ó¬O¥Ñ°V½m¨}¦nªº¨àµ£´Á¯«¸g¦æ¬°¯e±wªº±M®a¤p¤ß¦a¤U¦¹¶EÂ_¡Cµo®iªº°ÝÃD¡A¯S§O¬O»y¨¥µo®i¿ð½w¡A©MÀô¹Ò¾AÀ³ªº°ÝÃD¡A¦³®É·|«Ü¹³ADHD¡CªvÀøÀ³µÛ­«¦b±N«Ä¤l¦w¸m¦bµ²ºc¤Æªº¾Ç«eÀô¹Ò¥H¤Î¤÷¥Àªº°V½m©M¤ä«ù¡C¿³¾Ä¾¯¥i¥H­°§C¹ï¥ßªº¦æ¬°©M§ïµ½¥À¤lªº¤¬°Ê¡A¦ý¬O¥¦­Ì³q±`¥u¥Î¦bÄY­«ªº­Ó®×¡A©Î¬O«Ä¤l¦bÀô¹Ò©Î¦æ¬°³B²z¤§«á¡A¯gª¬¤´µM¥¼§ïµ½®É¡C


  °Ý¡GADHD¹ï±wµ£¤Î¥L­Ì®a®xªº½ÄÀ»¦³­þ¨Ç¡H
 
榭G

¥Í¬¡¹ïADHD±wµ£¥i¥H¬O«Ü¨¯­Wªº¡A¥L­Ì¬O¨º¨Ç±`¦b¾Ç®Õ·S¤W³Â·Ð¡BµLªk§¹¦¨¤@¶µ¹CÀ¸¡A¦Ó¥B«ÜÃø¥æªB¤Íªº¤H¡C¥L­Ì¥i¯à¨C±ßªá¤W­W´eªº¼Æ¤p®É¡A§V¤O¦aºû«ù¤ß«ä¦b®a®x§@·~¤W¡AµM«á§Ñ°O±a¥h¾Ç®Õ¡C¹ï«Ä¤l©Î¥L­Ìªº®a¤H¨Ó»¡¡A¤é´_¤@¤é­±¹ï³o¨Ç®À§é¨Ã¤£¬O¤@¥ó®e©öªº¨Æ¡A®a®x½Ä¬ð¥i¯à¼W¥[¡C¦¹¥~¡A©M¦P¾«¤Î¤Í½Ëªº°ÝÃD±`¥X²{¦bADHD±wµ£¨­¤W¡C¦b«C¬K´Á¡A³o¨Ç«Ä¤l¦³¸û°ªªº¦MÀI©Ê·|µo¥Í¥æ³q·N¥~¡B©â·Ï¡B¤Ó¦­Ãh¥¥©M¸û§Cªº±Ð¨|µ{«×¡C·í«Ä¤l³Q¶EÂ_¦³ADHD®É¡A¤÷¥À»Ý­n¥J²Ó¦a«ä¦ÒªvÀøªº¤è¦¡¡A¦Ó¥B·í¤÷¥À¬°«Ä¤l´M¨DªvÀø®É¡A¦]¬°ADHD©M¨ä¥Lºë¯«¯e¯fªºªvÀø³q±`µLªk¥Ñ«OÀI¤ä¥I¡A®a®x·|­±Á{¯Ó¶O¤j¶qª÷¿úªº±¡§Î¡C«Ü¦h¾Ç®Õ¨S¦³¨ó§U³q±`©MADHD±wµ£¬ÛÃö°ÝÃD¡]ªÀ¥æ§Þ¥©©M¦æ¬°°V½m¡^ªº­p¹º¡A¦¹¥~¡A¤£¬O©Ò¦³ADHDªº±wµ£³£²Å¦X¯S®í±Ð¨|ªº¸ê®æ¡C³o¨Ç³£¾É­P«Äµ£¨S¦³¨ü¨ì¥¿½T¤Î¾A·íªºªvÀø¡C­n§JªA³o¨Ç»Ùê¡A®aªø¥i¯à·|·Q­n´M§ä¥H¾Ç®Õ¬°°ò¦ªº­p¹º¡A¨ä¤¤¥]¬A®aªø¡B¦Ñ®v¡B¾Ç®Õ¤ß²z®v¡B¨ä¥L¤ß²z½Ã¥Í±M®a©MÂå®v©Ò§Î¦¨ªº¹Î¶¤ªvÀø¡C


  °Ý¡GADHD¨S¦³­¹ª«Àøªk¶Ü¡H
 
µª¡G ³\¦h®aªø¦b´M¨DÂåÀø¤§«e¹Á¸Õ¹L¦hºØªº¶¼­¹Àøªk¡A¹³¬O¶¼­¹¤¤¤£§t¿}¡C¦ý¬O¨S¦³½T¤Áªº¶¼­¹ªvÀø¥i¥HÅã¥Ü¹ï¤j³¡¤ÀªºADHD±wµ£¦³¤@­PªºÀø®Ä¡A¤Ö¼Æªº¬ã¨sÅã¥Ü¤@¨Ç±wµ£¥Î³o¨Ç¤èªk¥i¯à¦³®Ä¡A¦ý¬O©µ¿ð¨Ï¥Î½T©wªº¡B¦³®ÄªºªvÀø¦Ó¥h°l¨D¥¼ª¾ªº¡B³q±`µLªkÃÒ©úªº¹L±Ó­ì¡A¥i¯à¹ï«Ü¦h«Ä¤l¦³®`¡C

  °Ý¡G¦æ¬°ªvÀø¬O¤°»ò¡H
 
µª¡G ¥Î¦bADHD±wµ£ªº¦æ¬°ªvÀø¦³´XºØ¤£¦Pªº§Î¦¡¡A¥]¬A¤ß²zªvÀø¡B»{ª¾¦æ¬°ªvÀø¡BªÀ¥æ§Þ¥©°V½m¡B¤ä«ù¹ÎÅé¡A¥H¤Î¤÷¥À©M±Ð¨|ªÌ§Þ¥©°V½m¡C¬ü°ê°ê®aºë¯«½Ã¥Í¬ã¨s°|¹ïª`·N¤O¯Ê³´¹L°Ê¯g±wµ£¦hºØªvÀø¤è¦¡ªº¬ã¨s¡]NIMH Multimodal Treatment Study of Children with ADHD, MTA¡^¨Ï¥Î¤@ºØ«D±`±K¶°ªº¦æ¬°ªvÀø¡A¥]¬A«Ä¤lªº¦Ñ®v¡B®a®x¡A©M°Ñ»P¤@­Ó¥þ¤Ñ¡B¬°´Á¤K¶gªº®L¥OÀç¡C¾á¥ô¿Ô¸ßªºªvÀøªÌ¡]consulting therapist¡^©M¦Ñ®v¤@°_°w¹ï¼vÅT±Ð«Ç¦æ¬°©M¾Ç·~ªí²{ªº¦æ¬°°ÝÃDµo®i¦æ¬°³B²zªº­p¹º¡C¨ü¹L°V½mªº±Ð®v§U²z©M«Ä¤l¤@°_¦b¥L©Î¦oªº±Ð«ÇùØ12¶g¡A´£¨Ñ¤ä«ù©M¼W±j¾A·íªº¡B¦b¤u§@¤Wªº¦æ¬°¡]on-task behavior¡^¡C®aªø³æ¿W©MªvÀø®v¨£­±¡A¨Ã¦b¤p¹ÎÅ餤¾Ç²ß³B²z¦b®a»P¦b®Õ°ÝÃDªº¤èªk¡C³o­Ó®L¥OÀç¥Ø¼Ð¦b§ïµ½ªÀ¥æ¦æ¬°¡B¾Ç·~ªí²{©M¹B°Ê§Þ¯à¡C

  °Ý¡G²{¦b¥Î¨ÓªvÀøADHDªºÃĪ«¦³­þ¨Ç¡H
 
µª¡G ºë¯«¿³¾Ä¾¯¡A¥]¬A?¾L¥Ò¯×¡]methylphenidate¡A°Ó«~¦W¡G§Q¥L¯à¡ARitalin¡^©M¦w«D¥L©R¡]amphetamine¡A°Ó«~¦W¡GDexedrine¡ADextrostat¡A©MAdderall¡^¡A¬O¨ì¥Ø«e¬°¤î¹ïADHD³Ì³Q¼sªx¬ã¨s©M´¶¹M³B¤èªºªvÀø¡A³\¦hµu´Áªº¬ã¨s¤w¸g½T©w¿³¾Ä¾¯©M¤ß²zªÀ·|Àøªk¡]psychosocial treatments¡^¥i¥H¦w¥þ¥B¦³®Ä¦a´î»´ADHDªº¯gª¬¡CNIMHªº¬ã¨s¤w¸g«ü¥X¹ï¤p¾ÇADHD±wµ£³Ì¦³®Äªº¨â­ÓªvÀø¼Ò¦¡¡A¤@¬°±K¤ÁºÊ±±ªºÃĪ«ªvÀø¡A¤@¬°¦X¨ÖÃĪ«©M±K¶°ªº¦æ¬°ªvÀø¡C¦b¬ü°ê°ê®aºë¯«½Ã¥Í¬ã¨s°|¹ïª`·N¤O¯Ê³´¹L°Ê¯g±wµ£¦hºØªvÀø¤è¦¡ªº¬ã¨s¡]NIMH Multimodal Treatment Study of Children with ADHD, MTA¡^¤¤¥]¬Aªñ¤»¦Ê­Ó¨Ó¦Û¤£¦P¦a°Ïªº°ê¤p¾Çµ£¡A¤E¦¨ªº«Ä¤l¦b¸g¹L¨ä¤¤¤@ºØªºªvÀø«á¦³©úÅ㪺§ïµ½¡C¦¹¥~¡A§Ü¼~Æ{¾¯¤]¦b«Ä¤l¹ï¿³¾Ä¾¯¤ÏÀ³¤£¦n¡B¦³µLªk§Ô¨üªº°Æ§@¥Î¡A©Î¬O¦³¦@¯f±¡ªp¡]¹³¬O©âÝz¯g¡BµJ¼{¡A©Î±¡·P©Ê¯e±w¡^®É³Q¥Î§@²Ä¤G½uªºªvÀøÃĪ«¡C¤TÀô§ÜÆ{¾¯¹ï¦Ê¤À¤§¤»¤Q¨ì¤C¤QªºADHD±wµ£¦³®Ä¡CÁöµM³o¨ÇÃĹï¤j³¡¤Àªº«Äµ£«Ü¦³À°§U¡AMTAªºµo²{«ü¥X³æ¿W¨Ï¥ÎÃĪ«¥i¯à¹ï«Ü¦h«Ä¤l¨Ó»¡¨Ã¤£¤@©w¬O³Ì¦nªº¡C¨Ò¦p¡A¦ñÀH¦³¨ä¥L°ÝÃD¡]¨Ò¦pµJ¼{¡B¦³À£¤Oªº®a®xÀô¹Ò¡BªÀ¥æ§Þ¥©¤£¨Îµ¥µ¥¡^ªº«Ä¤l¡A°£¤FADHDªº¯gª¬¤§¥~¡A¥i¯à¥i¥H±q¦X¨ÖªºªvÀø¤¤Àò±o³Ì¤jªºÀ°§U¡C

  °Ý¡G³o¨ÇÃĦ³¼Ð·Ç¾¯¶q¶Ü¡H
 
µª¡G ¦bªvÀøADHD±wµ£®É¡A¤p¤ßªºÃĪ«³B²z¬O«Ü­«­nªº¡C´N?¾L¥Ò¯×¡]methylphenidate¡A°Ó«~¦W¡G§Q¥L¯à¡^¦Ó¨¥¡A³q±`ªº¾¯¶q½d³ò¬O5¨ì20²@§J¡A¤@¤Ñµ¹¨â¨ì¤T¦¸¡C¦w«D¥L©R¡]°Ó«~¦W¡GDexedrine©MDextrostat©MAdderall¡^ªº¾¯¶q«h¬O?¾L¥Ò¯×¾¯¶qªº¤@¥b¡C¨C­Ó¤H»Ý­nªºÃĪ«¾¯¶q¤£¤@©w³£©MÅé­«¡B¦~Ä֩άO¯gª¬ªºÄY­««×¦³Ãö¡C¦b¨àµ£´Á¦]¬°Åé­«§t¯×ªÕ¸û¤Ö¡]increased lean body weight¡^¦Ó»Ý­n¸û°ªªº¾¯¶q¡A«C¬K´Á«á¥i¯à¥²»Ý´î¤Ö¾¯¶q¡A¨C­ÓÂå®v¥Î³o¨ÇÃĪº¤èªk·|²¤¦³¤£¦P¡C

  °Ý¡G«Ä¤l­nªA¥Î³o¨ÇÃĪ«¦hªøªº®É¶¡¡H
 
µª¡G ¹L¥h¤Q¦~¨Ó¡A¶V¨Ó¶V¦hÃÒ¾ÚÅã¥ÜªAÃĪº¦n³B«ùÄò¨ì«C¬K´Á©M¦¨¤H´Á¡A¦]¦¹¹w´ÁªºªAÃĮɶ¡¥[ªø¡CµM¦Ó¡A«Ü¦h¦]¯À³y¦¨¦b«C¬K´Á¥¼Ä~ÄòÃĪ«ªvÀø¡A¥]¬A³Ì©úÅ㪺¯gª¬³¡¤À®ø°£¡BÃĮĤӵu»Ý­n¤@¤ÑªA¥Î¦h¦¸¡A¥H¤Î»Ý­n©w´Á¥ÑÂå®v¶}¥ß³B¤è¡C¦¹¥~¡A®aªø±`±`¦b§Y¨ÏÃĪ«Åã¥Ü¦³®Ä¡B©Î¦]¬°«Ä¤l¶i¨B¦Ó»{¬°¤£¦A»Ý­nÃĪ«¦Ó°±ÃÄ¡C

  °Ý¡G³B¤è¿³¾Ä¾¯¦³¦hÀWÁc¡H
 
µª¡G 1995¦~ªº¸ê®ÆÅã¥Ü¡AªvÀø¨àµ£¤Î«C¤Ö¦~ªºÂå®v¶}¥ß¤F600¸U­Ó¿³¾Ä¾¯ÃĪ«ªº³B¤è¡X?¾L¥Ò¯×¡]°Ó«~¦W¡G§Q¥L¯à¡^©M¥k±Û¦w«D¥L©R¡]°Ó«~¦W¡GDexedrine¡^¡C¦b©Ò¦³¥Î¨ÓªvÀø¨àµ£ºë¯«¯e¯fªºÃĪ«¤¤¡A¿³¾Ä¾¯ÃĪ«³Q¬ã¨s±o³Ì¬°³z¹ý¡C

  °Ý¡G¿³¾Ä¾¯ªº¨Ï¥Î¬O¤£¬O¦b¼W¥[©O¡H
 
µª¡G ¦b¬ü°ê¡A¹L¥h25¦~¨Ó¿³¾Ä¾¯ªº¨Ï¥Î¼W¥[¤F³\¦h¡A³Ìªñªº¬ã¨sµo²{1990¨ì1995¤§¶¡?¾L¥Ò¯×ªº¨Ï¥Î¼W¥[¤F2.5­¿¡C³o­Ó¼W¥[¤j³¡¤À¬O¦]¬°¼WªøªvÀøªº®É¶¡¡A¥H¤Î¸û¦hªº¤k«Ä¤l¡B«C¤Ö¦~¡B¦¨¤H©M¤£±M¤ß¡]°£¤F¦P®É¦³¹L°Ê©M¤£±M¤ß /ª`·N¤O¯Ê³´¤§¥~¡^ªº¤H¤]³£±µ¨üªvÀø¡C

  °Ý¡G¿³¾Ä¾¯ªº¨Ï¥Î¦³ºØ±Ú®t²§¶Ü¡H
 
µª¡G ¤£¦PºØ±Úªº¨àµ£¥i¥Îªº¤ß²z½Ã¥ÍªA°È¦³«Ü©úÅ㪺®t²§¡A¦]¦¹¡AÃĪ«ªº¨Ï¥Î¤]¦³©Ò¤£¦P¡C¯S§O¬O¡A«D¸Ç¬üÄyªº¨àµ£¤ñ¥Õ¤H¨àµ£¦]¬°ºë¯«¯e¯f±µ¨üºë¯«ªvÀøªºÃĪ«¤Ö«Ü¦h¡A¥]¬A¿³¾Ä¾¯¡C

  °Ý¡G¬°¤°»ò¦b°ÝÃD¬O¹L¤À¦n°Ê®É¨Ï¥Î¿³¾Ä¾¯©O¡H
 
µª¡G ³o­Ó°ÝÃDªºµª®×¨Ã¥¼½T©w¡A¦ý¬O¤@­Ó²z½×ªí¥ÜADHD©MµLªk§í¨î¹ï¤º¦b©M¥~¦b¨ë¿Eªº¤ÏÀ³¦³Ãö¡C¨ì¥Ø«e¬°¤î¡A¦³ÃÒ¾ÚÅã¥Ü¤j¸£¤¤³Q»{¬°©M­p¹º¡B¦³»·¨£¡]foresight¡^¡B¿Å¶q´À¥Nªº¤ÏÀ³¡B©M¦bÀ³¸Ó¦Ò¼{¨ä¥L¸Ñ¨M¿ìªk®É§í¨î¦æ¬°ªº°Ï°ì¡A¦bADHDªº¤H¬O¤£°÷¬¡ÅD¡]underaroused¡^ªº¡C¿³¾Ä¾¯ÃĪ«¥i¯à§@¥Î¦b³o¨Ç¤j¸£ªº°Ï°ì¡A¼W¥[¯«¸g¬¡©Ê¨ì¸û¥¿±`ªºµ{«×¡A¦ý¬O¡A»Ý­n§ó¦hªº¬ã¨s¨Ó½T¥ß¿³¾Ä¾¯ªº§@¥Î©M¾÷Âà¡C

  °Ý¡G¨Ï¥Î¿³¾Ä¾¯©M¨ä¥LªvÀøªº­·ÀI¦³­þ¨Ç¡H
 
µª¡G ¿³¾Ä¾¯ÃĪ«¡A¦bÂåÀøºÊ·þ¤U¨Ï¥Î®É¡A³q±`³Q»{¬°¬O¬Û·í¦w¥þªº¡AÁöµM¥¦­Ì¦pªG³Q«C¤Ö¦~©M¦¨¤HÀݥη|³y¦¨¤WÅ}¡A¦ý¦b³Q³B¤èµ¹ADHD¨Ï¥Î®É¡A³o¨ÇÃĪ«¨Ã¥¼Åã¥Ü¦³¦¨Å}©Ê¡A¤]¤£·|³y¦¨ÃĪ«ÀݥΰÝÃD¡C¥¦­Ì«Ü¤ÖÅý¨àµ£Ä±±o¡u¤®¾Ä¡v¡]¡¨high¡¨¡^©Î¯«¸g¹L±Ó¡]jittery¡^¡A¤]¤£·|ÂíÀR«Ä¤l¡CÁöµMºë¯«¿³¾Ä¾¯ªø´Á®ÄªGªº¸ê®Æ«Ü¤Ö¡A¨S¦³ÃÒ¾ÚÅã¥Ü¤p¤ßªºªvÀø©Ê¨Ï¥Î¦³®`¡C·í¤£¨}ªºÃĪ«¤ÏÀ³¯uªº¥X²{®É¡A³q±`©M¾¯¶q¦³Ãö¡A¦Ó¥B¬O¥i°fªº¡C¤¤µ¥¾¯¶qªº°Æ§@¥Î¦³­°§C­¹¼¤©M¥¢¯v¡A³o¨Ç§@¥Î¦bªvÀø¦­´Á¥X²{¡A¦Ó¥B¥i¯àÀH®É¶¡¦Ó´î¤Ö¡C¥¦­Ì¥i¯à¹ï¦¨ªø³t²v¦³­t­±¼vÅT¡A¦ý¬O³Ì«áªº¨­°ª¬Ý°_¨Ó¨Ã¤£¨ü¼vÅT¡C

  °Ý¡G¦]ADHD¦ÓªA¥Î³o¨ÇÃĪ«ªº¨àµ£·|Åܦ¨ÃĪ«¦¨Å}ªÌ¶Ü¡H
 
µª¡G ¨Æ¹ê¤W¡A¬Ý°_¨Ó­è¦n¬Û¤Ï¡AÁöµMÃĪ«ÀݥΩM§l·Ï¦MÀI©Êªº¼W¥[©M¨àµ£´ÁADHD¦³Ãö¡A³o­Ó¦MÀI©Ê¬Ý°_¨Ó¤j³¡¤À¬O¦]¬°ADHDª¬ªpªº¥»¨­¡A¨Ã«DªvÀø¡C¦b¤@­Ó¥Ñ°ê®aºë¯«½Ã¥Í¬ã¨s°|¡]NIMH¡^©M°ê®aÃĪ«Àݥάã¨s°|¡]National Institute on Drug Abuse¡^¦@¦P¸ê§Uªº¬ã¨s¤¤¡A¥Î¿³¾Ä¾¯ªvÀøªºADHD¨kµ£«Ü©úÅã¦a¦b¥L­Ìªø¤j¤@ÂI«á¸û¤ÖÀÝ¥ÎÃĪ«©M°sºë¡C¦ý¬O­n«Ü¤p¤ß¡A¦]¬°¾ãÅ骺ÃÒ¾ÚÅã¥Ü¡A¦³ADHDªº¤H¡]¯S§O¬O¥¼ªvÀøªºADHD¡^ªº½T¦b¥¼¨Ó¦³¸û°ªªº¦MÀI©Ê·|¦³°sºë©Îª«½èÀݥΡC¦]¬°¤@¨Ç¬ã¨sªºµ²½×¤¬¬Û½Ä¬ð¡A»Ý­n§ó¦hªº¬ã¨s¨Ó¤F¸Ñ³o¨Ç²{¶H¡CµL½×¦p¦ó¡A¥Ñ©ó¯u¹ê¥B½T©wªºµo²{ADHD¨àµ£ªvÀø¤£¨¬¡]inadequate¡^©Î¥¼ªvÀø¬O¦³®`ªº¡A®aªø¤£À³¸Ó¦]¬°¦³¹ïÃĪ«ÀݥΦMÀI©Ê»~¸Ñªº©Î¸Ø±iªº«ÅºÙ¡A¦Ó³Qªý¤î´M¨D¦³®ÄªºªvÀø¡C

  °Ý¡G³Ìªñ¦b°ê®a½Ã¥Í¬ã¨s°|¡]NIH¡^¤£¬O¦³°w¹ïADHD¦ÓÁ|¦æªº¤j«¬·|ij¶Ü¡H
 
µª¡G ¦b1998¦~¡A°ê®a½Ã¥Í¬ã¨s°|Á|¦æ¤F¤@­Ó°w¹ïADHDªº¨â¤Ñ¦@ÃÑ·|ij¡]a two-day Consensus Conference on ADHD¡^¡AÁܽФF°ê¤º©M°ê»Úªº±M®a¡A¥H¤Î¨Ó¦ÛªÀ·|¤j²³ªº¥Nªí¡C³o­Ó¦@ÃÑ·|ijªºÁn©ú²{¦b¥i¨£©óhttp://odp.od.nih.gov/consensus/cons/110/110_statement.htm

  °Ý¡GADHD©M¨ä¥L¯e±w¡A¨Ò¦p¾Ç²ß»Ùê¡BµJ¼{¯e±w¡BÂù·¥©Ê¯e±w©Î¼~Æ{¯gªºÃö«Y¬°¦ó¡H
 
µª¡G ¤j³¡¤À¦bÁ{§É¤W¦³ªvÀøªºADHD³£¦³¦@¯f²{¶H¡]comorbidity¡^¡AADHD¥i¯à¦P®É¨Ö¦³¾Ç²ß»Ùê¡]15-25%¡^¡B»y¨¥¯e±w¡]30-35%¡^¡B¦æ¬°³W½d»Ùê¡]15-20%¡^¡B¹ï¥ß¤Ï§Ü¯g¡]°ª¹F40%¡^¡B±¡·P©Ê¯e±w¡]15-20%¡^¡A©MµJ¼{¯e±w¡]20-25%¡^¡C¦³©âÝz¯e±wªº¨àµ£°ª¹F¦Ê¤À¤§¤»¤Q¤]¦³ADHD¡C°O¾Ð¡B»{ª¾¾úµ{¡]cognitive processing¡^¡B¦³±ø²z¡]sequencing¡^¡B°Ê§@§Þ¯à¡BªÀ¥æ§Þ¥©¡B½Õ¾ã±¡ºü¤ÏÀ³©M¹ï³W½dªº¤ÏÀ³¥X²{»Ùê«Ü±`¨£¡AºÎ¯v¯e±w¤]«Ü±`¨£¡C

  °Ý¡GADHDªº¾ú¥v¬°¦ó¡H¥¦©MADD¦³¦óÃö³s¡H
 
µª¡G ¦b1970¦~¥N¦­´Á¡AADHD±q¹L°Ê¡]hyperkinesis¡A·½¦Û©Ô¤B¤åªºsuperactive¡^³Q§ïºÙ¬°¹L°Ê¡]hyperactivity¡^¡C¦b1980¦~¥N¡ADSM-IIIºÙ©I¦¹¯gª¬¬°ª`·N¤O¯Ê³´¯e±w¡]Attention Deficit Disorder©ÎADD¡^¡A¦¹¯e±w¥i¥H¶EÂ_¦ñÀH©Î¤£¦ñÀH¹L°Ê¡C³o­Ó©w¸q³Q³Ð³y¨Ó±j½Õ¤£±M¤ß©Îª`·N¤O¯Ê³´ªº­«­n©Ê¡A¦¹ª¬ªp±`±`¦ý¤£Á`¬O¦ñÀH¦³¹L°Ê¡CDSM-IIIªº­×­qª©¡ADSM-III-R¦b1987¦~µoªí¡A¦^¨ì±j½Õ§â¹L°Ê¥]¬A¦b¶EÂ_¤º¡A¥¿¦¡¦WºÙ¬°ADHD¡C¦bDSM-IV¥Xª©®É¡AADHDªº¦WºÙ¤´µMªu¥Î¡A¦ý¬O¦b³o­Ó¤ÀÃþ¤§¤U¦³¤£¦Pªº¨È«¬¡A¥]¬Aª`·N¤O¤£¨¬©M¹L°Ê¡Ð½Ä°Ê¨âªÌªº¯gª¬¡Aªí¥Ü¦³¤@¨Ç¤H¥u¦³¨ä¤¤¤@ºØ«¬ºA¸û¬°¥D­n¡]¦Ü¤Ö¦b¹L¥h¤»­Ó¤ë¡^¡C¦b°ê»Ú¯e¯f¤ÀÃþ¨t²Î¡]International Classification of Diseases¡A¥D­n¦b¨ä¥L¦è¤è°ê®a¨Ï¥Î¡^¨Ï¥Î¡u¹L°Ê¯g¡v¡]Hyperkinetic Disorder¡^³o­Ó¦WºÙ¡A¦ý¶EÂ_¼Ð·Ç©MADHD/¦X¨Ö«¬¡]combined type¡^¬O¤@¼Ëªº¡C

  °Ý¡GADHD¥¼¨Óªº¬ã¨s¤è¦V¬°¦ó¡H
 
µª¡G ±q«Ü¦h¤è­±¨Ó»¡¡A«ùÄò¬ã¨sADHD¬O¥²»Ýªº¡CADHD¹ïªÀ·|ªº½ÄÀ»»Ý­n³Q½T©w¡CÃö©ó³o¤è­±ªº¬ã¨s¥]¬A (1) ¦b¤£¦Pªº¾Ç®Õ©M¨àµ£°·±d·ÓÅ@¨t²ÎùجI¦æ¦³®ÄªºÃĪ«³B²z©Î¦X¨ÖªvÀøªº¤è®×¡A(2) ¶W¹L20·³¦³ADHDªº¦¨¤H¥H¤Î¥L­Ìªº®a®x©Ò¨ü¨ìªº½ÄÀ»©MÄY­««×¡A(3) ½T©w©MADHD¶EÂ_¤Î·ÓÅU¬ÛÃöªº¤ß²z½Ã¥Í³]¬Iªº¨Ï¥Î¡CÁٻݭn¨ä¥L¬ã¨s¨Ó§ïµ½±Ð¨|©M°·±d·ÓÅ@ªA°Èªº·¾³q¡A½T«O§ó¦³¨t²ÎªºªvÀø­p¹º¡C¤]»Ý­n°ò¦ªº¬ã¨s¨Óµ¹ADHDªº¦æ¬°©M»{ª¾ªº³¡¤À¸û¦nªº¬É©w¡A¤£¥u¬O¹ïADHDªº±wµ£¡A¤]¹ï¥¼±w¯fªº¨àµ£¡C³o­Ó¬ã¨sÀ³¸Ó¥]¬A (1) »{ª¾µo®i¡B»{ª¾©M±M¤ß¾úµ{¡B½Ä°Ê±±¨î¡B©M±M¤ß/¤£±M¤ßªº¬ã¨s¡A(2) °w¹ï¤wª¾¥i¯à¾É­P¥¼¨ÓADHD¦MÀI¦]¯Àªº¹w¨¾/¦­´ÁªvÀø­p¹ºªº¬ã¨s¡A©M (3) ¶}©l¥ÎÃĤ§«e¡A¥H¤Î°lÂܳo¨Ç¤H¨ì¦¨¤H´Á¤Î¤¤¦~ªº¸£³¡³y¼v¬ã¨s¡C³Ì«á¡A»Ý­n§ó¦hªº¬ã¨s¦b¨àµ£´Á©M¦¨¤HADHDªº¦@¯f¡]¦P®É¦@¦s¡^ªº±¡ªp¡A©MªvÀøªº·N²[¡]implication¡^¡C
 

 
  • The U.S. National Institute of Mental Health does not currently endorse foreign translation of any material contained in any NIMH publication and bears no responsibility for the accuracy of any translation or reproduction.
  • ¬ü°ê°ê®a½Ã¥Í¬ã¨s°|²{¶¥¬q¹ï©ó¥»°|µo¦æ¤å¥ó¤§«D­^»y½Ķª©¨Ã¤£¤©¥H­I®Ñ¡A¦P®É¤£¹ï¦¹Ãþ½Ķ¤å¥ó¤§·Ç½T©Ê­t¾á¥ô¦ó³d¥ô¡C
  • ­Y¹ï¥»¤å¦³¥ô¦óºÃ¸q¡A½Ð³w¬¢¤¤¤sÂå¾Ç¤j¾Çªþ³]Âå°|ºë¯«¬ì¨àµ£¤Î«C¤Ö¦~ºë¯«Âå¾ÇÂåÀø¹Î¶¤¡C
    ¥x¤¤¥«¥_¤Ù°Ï¤Ó­ì¸ô3¬q1142¸¹¡]04¡^22393855¤À¾÷3211


 
¶À²Qµa¤ß¨­¶E©Ò
¶À²Qµa¤ß¨­¶E©Ò ¥x¤¤¥«¾Ç¤h¸ô83¸¹4¼Ó (¤¤¤s°ó¹ï­±, ³Á·í³Ò¼Ó¤W)

ª©Åv©Ò¦³ © ¶À²Qµa¤ß¨­¶E©Ò. Taiwan Products, B2BChinaSources, B2BtaiwanSources